Company intelligence / Profile preview
APITBIO
Songpa-gu, Seoul, South Koreaapitbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
APITBIO is advancing a pipeline of first-in-class monoclonal and bispecific antibodies and ADCs. Its lead asset targets L1CAM for solid tumors, with animal studies showing complete remission using an ADC format. The company’s platforms enable rapid discovery and optimization of therapeutic antibodies with high productivity and low hydrophobicity. Four unlicensed products are available for partnering/licensing[2][3].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugatemRNA-based drugs (encoding antibodies)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on APITBIO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APITBIO.